Trials / Not Yet Recruiting
Not Yet RecruitingNCT06242392
The Correlation Between HRD Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer
The Correlation Between Homologous Recombination Deficiency Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 250 (estimated)
- Sponsor
- Fujian Cancer Hospital · Other Government
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Clinicopathological data were collected from ovarian cancer patients treated with PARP inhibitors, with follow-up imaging conducted before and after treatment. The efficacy was evaluated according to RECIST criteria, comparing the correlation between different HRD statuses and the efficacy of PARP inhibitors in ovarian cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | homologous recombination deficiency | Homologous Recombination Deficiency (HRD) refers to a disruption or deficiency in the homologous recombination repair (HRR) pathway, which is a crucial mechanism in cells for repairing DNA double-strand breaks (DSBs). This pathway is particularly important for maintaining genomic stability. |
Timeline
- Start date
- 2024-01-31
- Primary completion
- 2026-05-01
- Completion
- 2026-07-01
- First posted
- 2024-02-05
- Last updated
- 2024-02-05
Source: ClinicalTrials.gov record NCT06242392. Inclusion in this directory is not an endorsement.